German pharmaceutical company BioNTech(BNTXcandycrushcandy.US) continues to risecandycrushcandy, up 6.36% to $97.9. On the news front. BioNTech will present important clinical trial updates at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing progress in its multiple immuno-oncology product lines, including innovative treatments for a variety of cancers. The company's ambitious goal is to launch its first cancer immunotherapy by 2026 and gain approval for 10 cancer indications by 2030, a promising development for patients and investors.
